Display options
Cite
Bimonte S, Leongito M, Piccirillo M, et al. Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment. Infect Agent Cancer. 2016;11:38doi: 10.1186/s13027-016-0082-9.
Bimonte, S., Leongito, M., Piccirillo, M., de Angelis, C., Pivonello, C., Granata, V., & Izzo, F. (2016). Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment. Infectious agents and cancer, 1138. https://doi.org/10.1186/s13027-016-0082-9
Bimonte, Sabrina, et al. "Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment." Infectious agents and cancer vol. 11 (2016): 38. doi: https://doi.org/10.1186/s13027-016-0082-9
Bimonte S, Leongito M, Piccirillo M, de Angelis C, Pivonello C, Granata V, Izzo F. Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment. Infect Agent Cancer. 2016 Aug 12;11:38. doi: 10.1186/s13027-016-0082-9. eCollection 2016. PMID: 27525037; PMCID: PMC4981963.
Copy Download .nbib Format: NLM
Share it on

Infect Agent Cancer. 2016 Aug 12;11:38. doi: 10.1186/s13027-016-0082-9. eCollection 2016.

Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment.

Infectious agents and cancer

Sabrina Bimonte, Maddalena Leongito, Mauro Piccirillo, Cristina de Angelis, Claudia Pivonello, Vincenza Granata, Francesco Izzo

Affiliations

  1. Division of Abdominal Surgical Oncology, Hepatobiliary Unit, Istituto Nazionale per lo studio e la cura dei Tumori "Fondazione G. Pascale", - IRCCS, Via Mariano Semmola, 80131 Naples, Italy.
  2. I.O.S. & Coleman Srl, Naples, Italy.
  3. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli Federico II, Naples, Italy.

PMID: 27525037 PMCID: PMC4981963 DOI: 10.1186/s13027-016-0082-9

Abstract

Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide with high morbidity, mortality and increasing incidence. It is of note that the main curative therapies for HCC are hepatic resection and transplantation although the majority of patients at the time of presentation are not eligible for resection or orthotopic liver transplantation (OLT) due to the underlying cirrhosis. Currently, a variety of loco-regional therapies, including radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), microwave coagulation therapy (MCT), transarterial chemoembolization (TACE) and others, have been developed as alternative treatment options for HCC. Among these techniques, RFA is currently the most widely used treatment, due to its several advantages, such as safety and efficacy. To date, the effectiveness of RFA for HCC is reduced by the presence of residual tumor as a consequence of insufficient treatment. In order to ameliorate the effects of RFA on HCC, several in vivo studies, have been performed on its application as single or in combination treatment with drugs or others loco-regional therapies, by using rabbit VX2 liver model. This represents an ideal model of liver cancers and is widely used for imaging and other experimental studies due to the rapid growth of these tumors and their similarity to human hepatocellular carcinoma. In order to elucidate the therapeutic potential of RFA with adjuvant treatments for HCC, we reviewed the latest findings on the RFA-based studies in rabbit VX2 hepatocarcinoma models.

Keywords: Hepatocellular carcinoma; RFA; Radiofrequency ablation; Residual tumor; Vx2 tumors

References

  1. Nanoscale. 2016 Feb 21;8(7):4324-39 - PubMed
  2. PLoS One. 2014 Dec 26;9(12):e115949 - PubMed
  3. J Cell Mol Med. 2010 Oct;14(10):2448-59 - PubMed
  4. Oncologist. 2001;6(1):14-23 - PubMed
  5. Cardiovasc Intervent Radiol. 2011 Aug;34(4):824-32 - PubMed
  6. Br J Urol. 1997 Jul;80(1):116-22 - PubMed
  7. J Craniomaxillofac Surg. 2000 Oct;28(5):300-7 - PubMed
  8. Clin Liver Dis. 2001 Feb;5(1):161-73 - PubMed
  9. World J Gastroenterol. 2004 Apr 15;10(8):1137-40 - PubMed
  10. Int J Clin Exp Pathol. 2015 Nov 01;8(11):13945-56 - PubMed
  11. PLoS One. 2012;7(5):e37266 - PubMed
  12. Zhonghua Gan Zang Bing Za Zhi. 2002 Oct;10 (5):362-5 - PubMed
  13. Oncology. 2007;72 Suppl 1:72-5 - PubMed
  14. Am Surg. 1994 Dec;60(12):929-33 - PubMed
  15. J Endourol. 1997 Aug;11(4):251-8 - PubMed
  16. Eur J Gastroenterol Hepatol. 2001 Mar;13(3):291-4 - PubMed
  17. Cell Cycle. 2009 Oct 15;8(20):3267-73 - PubMed
  18. Lab Anim. 2004 Jan;38(1):79-84 - PubMed
  19. Surg Technol Int. 2002 Sep;10:99-106 - PubMed
  20. Dig Surg. 2008;25(6):473-80 - PubMed
  21. Acta Radiol. 2013 Jul;54(6):684-9 - PubMed
  22. Radiology. 1992 Apr;183(1):29-33 - PubMed
  23. Hepatol Res. 2016 Oct;46(11):1158-1161 - PubMed
  24. Eur Radiol. 2016 Oct;26(10 ):3474-82 - PubMed
  25. Invest Radiol. 2012 Feb;47(2):116-20 - PubMed
  26. J Natl Cancer Inst. 1968 Nov;41(5):1071-82 - PubMed
  27. Dig Surg. 2008;25(6):445-60 - PubMed
  28. World J Gastroenterol. 2014 Nov 28;20(44):16630-8 - PubMed
  29. Acta Radiol. 2015 Feb;56(2):133-42 - PubMed
  30. J Transl Med. 2012 Nov 21;10:230 - PubMed
  31. Infect Agent Cancer. 2014 Nov 24;9(1):39 - PubMed
  32. J Exp Med. 1935 Sep 30;62(4):523-48 - PubMed
  33. Acad Radiol. 1995 Sep;2(9):776-84 - PubMed
  34. Cancer Treat Rev. 2006 Dec;32(8):594-606 - PubMed
  35. J Exp Med. 1940 May 31;71(6):813-38 - PubMed
  36. Radiology. 2007 Oct;245(1):130-9 - PubMed
  37. Hepatol Res. 2009 Dec;39(12):1169-77 - PubMed
  38. Eur Radiol. 2003 Jun;13(6):1324-32 - PubMed
  39. Hepatol Int. 2008 Mar;2(1):116-23 - PubMed
  40. Radiology. 1995 Aug;196(2):517-20 - PubMed
  41. Radiology. 2000 Oct;217(1):119-26 - PubMed
  42. Int J Clin Exp Med. 2015 Jul 15;8(7):10739-45 - PubMed
  43. J Clin Gastroenterol. 2008 Sep;42(8):945-9 - PubMed
  44. J Vasc Interv Radiol. 2007 May;18(5):639-45 - PubMed
  45. J Biomed Mater Res A. 2007 Apr;81(1):205-13 - PubMed
  46. Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):353-67 - PubMed
  47. J Neurosurg. 1987 Jul;67(1):106-9 - PubMed
  48. Intern Med J. 2002 Aug;32(8):394-400 - PubMed
  49. Radiology. 1995 Nov;197(2):451-4 - PubMed
  50. Appl Neurophysiol. 1983;46(1-4):160-6 - PubMed
  51. Anticancer Agents Med Chem. 2008 Feb;8(2):123-31 - PubMed
  52. Diagn Interv Radiol. 2011 Dec;17(4):374-80 - PubMed
  53. Hepatology. 2010 Apr;51(4):1284-90 - PubMed
  54. AJR Am J Roentgenol. 2000 Jan;174(1):57-9 - PubMed
  55. J Ultrasound Med. 2010 Jan;29(1):51-60 - PubMed
  56. J Vasc Interv Radiol. 1992 May;3(2):291-7 - PubMed
  57. Br J Cancer. 1974 Jan;29(1):59-65 - PubMed
  58. PLoS One. 2013 Jun 28;8(6):e67355 - PubMed
  59. J Transl Med. 2013 Oct 29;11:273 - PubMed
  60. Ann Surg. 2009 Jan;249(1):20-5 - PubMed
  61. J Vasc Interv Radiol. 2009 Aug;20(8):1075-82 - PubMed
  62. Adv Surg. 2001;35:225-50 - PubMed
  63. Gut. 2016 Jan;65(1):134-43 - PubMed
  64. Exp Ther Med. 2012 Mar;3(3):386-390 - PubMed
  65. Urol Res. 2001 Oct;29(5):345-9 - PubMed
  66. World J Gastroenterol. 2010 Feb 28;16(8):927-33 - PubMed
  67. World J Gastroenterol. 2003 Feb;9(2):193-200 - PubMed
  68. Eur J Radiol. 2005 Oct;56(1):60-5 - PubMed
  69. J Vasc Interv Radiol. 2008 Jun;19(6):931-6 - PubMed
  70. N Engl J Med. 2011 Sep 22;365(12):1118-27 - PubMed
  71. Cancer. 1980 Jul 1;46(1):56-63 - PubMed
  72. Diagn Interv Radiol. 2014 Jul-Aug;20(4):335-40 - PubMed
  73. J Vasc Interv Radiol. 2015 Jul;26(7):1067-1075.e3 - PubMed
  74. J Hepatol. 1994 Feb;20(2):218-22 - PubMed
  75. J Gastrointestin Liver Dis. 2008 Dec;17(4):411-7 - PubMed
  76. Infect Agent Cancer. 2015 Mar 09;10:9 - PubMed
  77. J Transl Med. 2010 Jul 29;8:73 - PubMed

Publication Types